In a report issued on July 6, Andrew Fein from H.C. Wainwright reiterated a Buy rating on BELLUS Health (BLU), with a price target of $28.00. The company’s shares closed last Wednesday at $2.97, close to its 52-week low of $2.52.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 14.6% and a 49.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Deciphera Pharmaceuticals.
BELLUS Health has an analyst consensus of Moderate Buy, with a price target consensus of $9.74, implying a 210.2% upside from current levels. In a report issued on July 6, Jefferies also maintained a Buy rating on the stock with a $6.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.03 and a one-year low of $2.52. Currently, BELLUS Health has an average volume of 2.71M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
Read More on BLU:
